Amyotrophic Lateral Sclerosis (ALS) Market Size, Share, Industry, Forecast and outlook (2023-2030)

Amyotrophic Lateral Sclerosis (ALS) Market is segmented By Drug (Rilutek (Riluzole), Edaravone (Radicava), Others), By Treatment Type (Physical therapy, Speech Therapy, Medication, Respiratory Therapy, Others), By End-User (Diagnostic Centers, Hospitals, Clinics, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030.

Amyotrophic Lateral Sclerosis (ALS) Market Overview

The Global Amyotrophic Lateral Sclerosis Market size reached USD 0.7 billion in 2022 and is projected to witness lucrative growth by reaching up to USD 1.0 billion by 2030. The global amyotrophic lateral sclerosis market is expected to exhibit a CAGR of 5.1% during the forecast period (2023-2030). The Amyotrophic Lateral Sclerosis (ALS) market is characterized by the development and availability of therapies aimed at managing the symptoms and slowing the progression of the disease.

ALS, also known as Lou Gehrig's disease encompasses various treatment approaches, including medications, assistive devices, and supportive care. Ongoing research efforts focus on identifying potential disease-modifying treatments and innovative therapies to enhance patients' quality of life. 

With an increasing understanding of the disease's pathophysiology, the ALS market continues to evolve. The global amyotrophic lateral sclerosis market is driven by the factors such as the rising prevalence of amyotrophic lateral sclerosis, increasing awareness, advances in research and development activities, and technological advancements in treatment options.

Amyotrophic Lateral Sclerosis (ALS) Market Scope

To know more insights Download Sample

Amyotrophic Lateral Sclerosis (ALS) Market Dynamics

Advancements in Research and Developments Drive the Growth of the Amyotrophic Lateral Sclerosis Market

Research and development activities have led to the development of innovative therapies for ALS. This includes the exploration of gene therapy, stem cell therapy, and neuroprotective agents that aim to slow down disease progression, improve symptom management, and potentially provide disease-modifying effects. The introduction of these novel therapies expands the treatment options available to patients and drives market growth.

Ongoing research efforts aim to deepen the understanding of ALS, including its underlying causes, genetic factors, and disease progression mechanisms. Advancements in this area help researchers identify new therapeutic targets and develop more effective treatment approaches.

For instance, on April 25, 2023, Biogen Inc. announced that the U.S. Food and Drug Administration (FDA) approved QALSODY (tofersen) 100 mg/15mL injection for the treatment of amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene. This indication is approved under accelerated approval based on a reduction in plasma neurofilament light chain (NfL) observed in patients treated with QALSODY. 

Rising Awareness Drives the Growth of the Amyotrophic Lateral Sclerosis Market

Awareness campaigns empower ALS patients and their caregivers to become active advocates for their own care. Patient advocacy groups work tirelessly to raise awareness about ALS, improve access to healthcare services, and influence policy decisions. These efforts help amplify the voices of ALS patients, ensure their needs are considered, and drive positive change in the healthcare system. Through awareness, patients can navigate the complex healthcare landscape more effectively, access relevant resources, and participate in clinical trials or research studies.

For instance, Amyotrophic Lateral Sclerosis (ALS) Awareness Month has been observed in May in the U.S. since 1992. This year’s efforts will continue to unite and support those living with the neurodegenerative disease, which is estimated to impact around 30,000 people in the U.S., with about 5,000 new cases being diagnosed each year.

Limited Treatment Options Will Hamper the Growth of the Market

With limited treatment options, the potential market size for ALS therapies is constrained. The lack of a curative or transformative therapy narrows the patient population that can benefit from specific treatments, limiting the market's reach and growth prospects.

The limited treatment options create a less competitive market environment. With fewer approved therapies, there may be reduced competition among pharmaceutical companies, leading to less innovation and slower progress in treatment development. This lack of competition can hinder market growth and limit advancements in therapeutic options.

For more details on this report – Request for Sample 

Amyotrophic Lateral Sclerosis (ALS) Market Segment Analysis

The global amyotrophic lateral sclerosis market is segmented based on drug type, treatment type, end-user, and region.

The Edaravone (Radicava) Segment Accounted for Approximately 36.7% of the Amyotrophic Lateral Sclerosis Market Share

Being an approved and widely used drug for ALS, Edaravone has gained significant market share within the drug segment. Its dominance can be attributed to its specific indication for ALS treatment, its demonstrated effectiveness, and its availability in various markets. 

Edaravone, the active ingredient in Radicava, is a free-radical scavenger, meaning it helps to remove the reactive molecules that can contribute to oxidative stress. By removing these toxic molecules and lowering oxidative stress, it is expected to reduce nerve damage and slow ALS progression. The effective action and wide acceptance and availability of edaravone can lead to market dominance.

For instance, on February 10, 2023, Mitsubishi Tanabe Pharma Canada, Inc., a subsidiary of Mitsubishi Tanabe Pharma America, Inc. announced that RADICAVA Oral Suspension, the oral formulation of RADICAVA IV(edaravone), is commercially available in Canada for the treatment of patients with ALS.

Source: DataM Intelligence Analysis (2023)

Global Amyotrophic Lateral Sclerosis (ALS) Market Geographical Penetration

North America Accounted for Approximately 40.4% of the Market Share in 2022, Owing to the Advanced Healthcare Infrastructure and Technological Advancements

North America, particularly the United States and Canada, possess well-developed healthcare systems with robust infrastructure, including hospitals, specialty Specialty Clinics, research institutions, and rehabilitation centers. This infrastructure facilitates the diagnosis, treatment, and management of ALS patients, driving market growth.

North America is at the forefront of technological advancements in medical devices, diagnostic tools, and assistive technologies. These innovations play a critical role in enhancing the quality of life for ALS patients. Advanced mobility aids, communication devices, respiratory support systems, and other assistive technologies are readily available in the region, contributing to market dominance.

Source: DataM Intelligence Analysis (2023)

Amyotrophic Lateral Sclerosis (ALS) Market Companies 

The major global players in the amyotrophic lateral sclerosis market include Sanofi S.A., Brainstorm Cell Therapeutics, Biogen Inc., Bausch Health, F Hoffmann-la Roche Ltd, Ionis Pharmaceuticals, Mylan Pharma, Sun Pharma, Orion Pharmaceuticals, and AB Science. 

COVID-19 Impact on Amyotrophic Lateral Sclerosis (ALS) Market

Russia Ukraine Conflict Analysis

The Russia-Ukraine conflict is estimated to have a moderate impact on the global amyotrophic lateral sclerosis market. The conflict between Russia and Ukraine can lead to disruptions in the global supply chain, including pharmaceutical manufacturing and distribution. If key ALS medications or treatment components are produced or sourced from these regions, supply shortages or delays could occur, affecting the availability and accessibility of treatments in the global market.

By Drug Type

• Rilutek (Riluzole)
• Edaravone (Radicava)
• Others

By Treatment Type

• Physical Therapy
• Speech Therapy
• Medication
• Respiratory Therapy
• Others

By End User

• Hospitals
• Research and Academic institutes
• Specialty Clinics
• Others

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • The U.K.
  • France
  • Spain
  • Italy
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
• Middle East and Africa

Key Developments

• On June 14, 2023, Coya Therapeutics, Inc., a clinical-stage biotechnology company developing biologics intended to enhance Treg function, announced the appointment of Dr. Michelle Frazier, Ph.D. to Coya’s management team as Senior Vice President of Regulatory Affairs. Dr. Frazier will leverage her regulatory and CMC expertise to guide and oversee all of Coya’s regulatory submissions including the upcoming IND submission for COYA 302 for the treatment of Amyotrophic Lateral Sclerosis (ALS).
• On May 17, 2023, PatientsLikeMe (PLM), the trusted digital platform that empowers over 850K patients to navigate their health journeys, announced that it has partnered with the Neurological Clinical Research Institute (NCRI) at Massachusetts General Hospital (MGH) to share de-identified patient data that can improve research outcomes for amyotrophic lateral sclerosis (ALS). This news was announced onsite at the 2nd Annual ALS Drug Development Summit. With this collaboration, the company’s outcomes-rich data is now freely available to the international research community. This dataset will be a significant addition to Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) database comprising anonymized data from 29 clinical trials and 11,685 patient records. Both datasets will be hosted and maintained by the NCRI.
• On June 02, 2023, CureALS, a pioneering nonprofit organization dedicated to eliminating ALS (Amyotrophic Lateral Sclerosis) and other complex neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and Frontotemporal Dementia, officially launched. The organization's founder, former NCR Chairman and CEO Bill Nuti, who retired from his position in 2018 after being diagnosed with ALS, is on a mission to create a first of its kind, start-up where researcher support, public/private partnership, data sourcing and the use of artificial intelligence (AI) technology is the core of the program.

Why Purchase the Report?

• To visualize the global amyotrophic lateral sclerosis market segmentation based on drug type, treatment type, end-user, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development. 
• Excel data sheet with numerous data points of amyotrophic lateral sclerosis market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global amyotrophic lateral sclerosis market report would provide approximately 53 tables, 54 figures, and 195 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

For more Pharmaceuticals related reports, please click here